Skip to main content

Table 2 Results of the two Phase III open-label clinical trials

From: MMV in partnership: the Eurartesim® experience

Study PCR-corrected cure rate (mITT)
  Eurartesim AS+MQ A+L
DM040010 (n=1087) 97.0% 95.3% -
DM040011 (n=1524) 92.7% - 94.8%
  1. A+L: artemether+lumefantrine; AS+MQ: artesunate+mefloquine; mITT:modified intention-to-treat (defined as all randomized patients whoreceived at least one dose of study treatment, with the exclusion ofthose patients lost to follow-up for unknown reasons); PCR:polymerase chain reaction.